Clinical Trials Logo

Recurrent Childhood Ependymoma clinical trials

View clinical trials related to Recurrent Childhood Ependymoma.

Filter by:

NCT ID: NCT00326664 Completed - Clinical trials for Recurrent Childhood Ependymoma

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Start date: March 2006
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00101270 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

Start date: March 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as oxaliplatin and irinotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Oxaliplatin may help irinotecan kill more cancer cells by making cancer cells more sensitive to the drug. Giving oxaliplatin together with irinotecan may kill more cancer cells.

NCT ID: NCT00100880 Completed - Clinical trials for Recurrent Childhood Ependymoma

Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors

Start date: November 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with recurrent, progressive, or refractory CNS tumors. Lenalidomide may stop the growth of CNS tumors by blocking blood flow to the tumor. It may also stimulate the immune system in different ways and stop tumor cells from growing.

NCT ID: NCT00095940 Completed - Clinical trials for Recurrent Childhood Ependymoma

Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors

Start date: October 2004
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

NCT ID: NCT00091182 Completed - Clinical trials for Recurrent Rectal Cancer

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

Start date: October 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00077454 Completed - Clinical trials for Recurrent Neuroblastoma

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

Start date: February 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of erlotinib when given with temozolomide in treating young patients with recurrent or refractory solid tumors. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving erlotinib with temozolomide may kill more tumor cells.

NCT ID: NCT00063973 Completed - Clinical trials for Recurrent Childhood Ependymoma

Cilengitide in Treating Children With Refractory Primary Brain Tumors

Start date: July 2003
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of cilengitide in treating children with recurrent, progressive, or refractory primary CNS tumors. Cilengitide may slow the growth of brain cancer cells by stopping blood flow to the tumor.

NCT ID: NCT00053963 Completed - Clinical trials for Refractory Chronic Lymphocytic Leukemia

FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia

Start date: September 2002
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die

NCT ID: NCT00052780 Completed - Clinical trials for Recurrent Childhood Ependymoma

Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors

Start date: October 2002
Phase: Phase 1
Study type: Interventional

Phase I trial to study the safety of combining O6-benzylguanine with temozolomide in treating children who have recurrent or refractory brain tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. O6-benzylguanine may increase the effectiveness of temozolomide by making tumor cells more sensitive to the drug.

NCT ID: NCT00012181 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas

Start date: April 2001
Phase: Phase 1
Study type: Interventional

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of flavopiridol in treating children who have relapsed or refractory solid tumors or lymphoma.